Get started
Author

Louise R. Rodino‐Klapac

Observed names: L. Rodino-Klapac, L.R. Rodino-Klapac, LR Rodino-Klapac
OpenAlex ID: A5084358696
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP ‐9001‐103 ( ENDEAVOR )
2023 · Craig M. Zaidman, Crystal M. Proud, et al. · Annals of Neurology · 106
PDF
P54 T-cell response to SRP-9001 dystrophin transgene in a patient treated with Delandistrogene Moxeparvovec: a case of immune-mediated myositis
2023 · S. Khan, H. Haegel, et al. · Neuromuscular Disorders · 4
Limb Girdle Muscular Dystrophies
2020 · E. Pozsgai, E. Peterson, et al. · Neuromuscular Disorders · 4
Development of a validated Western blot method for quantification of human dystrophin protein used in Phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) (P5.105)
2017 · FJ Schnell, C Donoghue, et al. · Neurology · 4
Clinical Trial Highlights
2019 · L. Rodino-Klapac, E. Pozsgai, et al. · Neuromuscular Disorders · 3
425P Five-year outcomes with delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD): a phase 1/2a study
2024 · J. Mendell, Z. Sahenk, et al. · Neuromuscular Disorders · 2
P.128 Integrated analyses of data from clinical trials of delandistrogene moxeparvovec in DMD
2022 · C. Zaidman, P. Shieh, et al. · Neuromuscular Disorders · 2
P.134a Phase 1/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update
2022 · J. Mendell, Z. Sahenk, et al. · Neuromuscular Disorders · 2
SMA THERAPIES I
2018 · R. Shell, S. Al-Zaidy, et al. · Neuromuscular Disorders · 2
Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Longitudinal Comparison to External Controls on Six-Minute Walk Test (6MWT) and Loss of Ambulation (LOA) (S42.004)
2017 · JR Mendell, N Goemans, et al. · Neurology · 2
Eteplirsen for the Treatment of Duchenne Muscular Dystrophy (DMD) (S42.001)
2017 · JS Charleston, FJ Schnell, et al. · Neurology · 2
Development of a validated Western blot method for quantification of human dystrophin protein used in phase 2 and 3 clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy
2017 · F.J. Schnell, C. Donoghue, et al. · Neuromuscular Disorders · 2
Eteplirsen, a Phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): Clinical update
2015 · E. Kaye, J. Mendell, et al. · Neuromuscular Disorders · 2
PP09.16 – 2691: Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): 3.2 year update on six-minute walk test (6MWT), pulmonary function testing (PFT), and safety
2015 · E.M. Kaye, J.R. Mendell, et al. · European Journal of Paediatric Neurology · 2
424PDelandistrogene moxeparvovec micro-dystrophin expression and safety in 3–4-year-olds with Duchenne muscular dystrophy in ENDEAVOR and ENVOL studies
2025 · C. McDonald, J. Mendell, et al. · Neuromuscular Disorders · 1
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population
2025 · Yogesh Patel, Larry Orogun, et al. · CPT Pharmacometrics & Systems Pharmacology · 1
PDF
P.129 One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec in boys with DMD
2022 · C. Zaidman, C. Proud, et al. · Neuromuscular Disorders · 1
P.197 Evaluating pharmacology and efficacy of delandistrogene moxeparvovec in young and aged DMDMDX rats
2022 · R. Potter, C. Wier, et al. · Neuromuscular Disorders · 1
DMD - TREATMENT
2021 · C. Zaidman, C. Proud, et al. · Neuromuscular Disorders · 1
DMD – THERAPY
2020 · J. Mendell, Z. Sahenk, et al. · Neuromuscular Disorders · 1
Long-term treatment with eteplirsen promotes exon 51 skipping and novel dystrophin protein production in Duchenne muscular dystrophy patients
2016 · J. Charleston, F. Schnell, et al. · Neuromuscular Disorders · 1
Development of a validated western blot method for quantification of human dystrophin protein
2016 · F. Schnell, C. Donoghue, et al. · Neuromuscular Disorders · 1
176P3-Year functional outcomes of patients with Duchenne muscular dystrophy: pooled delandistrogene moxeparvovec clinical trial data vs external controls
2025 · J. Mendell, A. Connolly, et al. · Neuromuscular Disorders
424P Micro-dystrophin expression and safety with delandistrogene moxeparvovec gene therapy for DMD in a broad population: phase 1B trial (ENDEAVOR)
2024 · C. Proud, C. Zaidman, et al. · Neuromuscular Disorders
19O Muscle MRI outcomes in patients with Duchenne muscular dystrophy treated with delandistrogene moxeparvovec: findings from EMBARK Part 1
2024 · K. Vandenborne, G. Walter, et al. · Neuromuscular Disorders
Works count: 40
Citation count: 147
H-index: 4
I10-index: 1
Year
Topic
Type